Vantage Biosciences has completed enrollment in the phase 2 SeeClear study, evaluating oruvestat (VX-01), an investigational, orally administered inhibitor of amine oxidase copper containing 3 (AOC3), in patients with moderate-to-severe nonproliferative diabetic retinopathy (NPDR). The study met its recruitment target across all participating sites in the United States, Australia, and Southeast Asia, and topline data are anticipated in the fourth quarter of 2027, the company said in a press release. 

SeeClear is a randomized, double-masked, placebo-controlled phase 2 study being conducted at 26 sites. Participants are randomized to receive oruvestat or placebo for 52 weeks, a treatment period intended to capture clinically meaningful disease progression. All participants have now entered the treatment and follow-up phase. 

Oruvestat is a selective oral inhibitor of AOC3, a dual-function enzyme involved in the inflammation and neurovascular dysfunction underlying NPDR. AOC3 also contributes to leukocyte adhesion and to oxidative stress in the retinal microvasculature, processes implicated in the inflammation and neurovascular dysfunction that characterize diabetic retinopathy. Oruvestat was designed to achieve sustained AOC3 inhibitory exposure in ocular tissue following oral dosing. RP